Table 4 Effect of theaflavin and thearubigins and their combination based intervention on selected traits of normal and renal malfunctional rats at the termination of the study (56th day)
Parameters | Base line values (n = 1) | Treatments | Post treatment values at termination of study Control Study (Normal Rats) | Post treatment values at termination of study Arginine induced renal malfunctional rats |
|---|---|---|---|---|
Body weight (at the termination of study) | 128 ± 10.25 | T0 | 224.18 ± 10.25a | 223 ± 9.61a |
T1 | 212.14 ± 9.23d | 213.10 ± 6.11c | ||
T2 | 216.41 ± 8.56b | 217.74 ± 5.61b | ||
T3 | 213.12 ± 9.22c | 214.17 ± 4.25c | ||
TC (mg/dL) | 77.80 ± 3.56 | T0 | 85.14 ± 4.12a | 86.31 ± 4.63a |
T1 | 82.13 ± 3.25c | 81.14 ± 2.12c | ||
T2 | 84.15 ± 2.212b | 82.99 ± 5.63b | ||
T3 | 83.1 ± 3.14c | 82.29 ± 4.25b | ||
LDL-C (mg/dL) | 26.56 ± 3.56 | T0 | 27.10 ± 0.96a | 33.36 ± 2.13a |
T1 | 26.01 ± 1.01c | 30.94 ± 1.22c | ||
T2 | 26.65 ± 0.95b | 32.20 ± 3.61b | ||
T3 | 26.30 ± 1.02b | 31.49 ± 2.81b | ||
HDL-C (mg/dL) | 32.56 ± 3.56 | T0 | 38.45 ± 1.1 | 38.54 ± 2.36 |
T1 | 39.21 ± 0.96 | 39.70 ± 2.32 | ||
T2 | 39.01 ± 0.85 | 38.92 ± 1.09 | ||
T3 | 39.14 ± 0.89 | 39.64 ± 1.56 | ||
TG (mg/dL) | 58.26 ± 3.56 |  | 69.45 ± 1.20a | 67.15 ± 4.20 |
T1 | 67.12 ± 1.14c | 64.96 ± 5.15 | ||
T2 | 68.01 ± 1.05b | 65.20 ± 4.12 | ||
T3 | 67.65 ± 1.08c | 65.13 ± 2.12 | ||
Glucose (mg/dL) | 79.63 ± 3.72 | T0 | 85.65 ± 2.2a | 89.18 ± 6.14a |
T1 | 83.15 ± 1.96b | 84.70 ± 6.13b | ||
T2 | 83.69 ± 1.12b | 85.60 ± 3.20b | ||
T3 | 82.38 ± 1.23c | 83.98 ± 7.14b | ||
Insulin μU/Ml | 6.23 ± 0.56 | T0 | 8.25 ± 0.01b | 7.76 ± 0.22b |
T1 | 8.91 ± 0.25a | 8.06 ± 0.41a | ||
T2 | 8.80 ± 0.31b | 7.96 ± 0.52ab | ||
T3 | 8.99 ± 0.21a | 8.11 ± 0.12a | ||
Serum Urea mg/Dl | 32.56 ± 1.03 | T0 | 26.14 ± 1.01a | 37.83 ± 2.46a |
T1 | 25.96 ± 1.04b | 34.09 ± 2.56b | ||
T2 | 26.01 ± 0.96a | 34.95 ± 2.91b | ||
T3 | 25.78 ± 0.88b | 33.44 ± 1.45c | ||
Serum creatinine (mg/dL) | 1.01 ± 0.02 | T0 | 0.719 ± 0.01 | 1.15 ± 0.03a |
T1 | 0.715 ± 0.02 | 1.08 ± 0.01b | ||
T2 | 0.716 ± 0.01 | 1.09 ± 0.021b | ||
T3 | 0.701 ± 0.03 | 1.04 ± 0.05c | ||
Serum glutathione (mg/L) | 42.32 ± 1.02 | T0 | 50.52 ± 1.01b | 43.12 ± 3.01c |
T1 | 52.99 ± 1.45ab | 46.19 ± 2.56b | ||
T2 | 52.14 ± 1.21ab | 44.91 ± 4.14bc | ||
T3 | 53.01 ± 1.24a | 47.87 ± 4.12a | ||
Malonialdehyde (MDA) (mmol/L) | 6.23 ± 0.59 | T0 | 7.85 ± 0.14a | 8.01 ± 0.21a |
T1 | 6.23 ± 0.18b | 6.78 ± 0.24c | ||
T2 | 7.15 ± 0.12a | 7.55 ± 0.01a | ||
T3 | 6.85 ± 0.13ab | 6.95 ± 0.42b | ||
AST (IU/L) | 6.23 ± 0.59 | T0 | 7.85 ± 0.14a | 8.01 ± 0.21a |
T1 | 6.23 ± 0.18b | 6.78 ± 0.24c | ||
T2 | 7.15 ± 0.12a | 7.55 ± 0.01a | ||
T3 | 6.85 ± 0.13ab | 6.95 ± 0.42b | ||
ALT(IU/L) | 6.23 ± 0.59 | T0 | 7.85 ± 0.14a | 8.01 ± 0.21a |
T1 | 6.23 ± 0.18b | 6.78 ± 0.24c | ||
T2 | 7.15 ± 0.12a | 7.55 ± 0.01a | ||
T3 | 6.85 ± 0.13ab | 6.95 ± 0.42b | ||
ALP(IU/L) | 6.23 ± 0.59 | T0 | 7.85 ± 0.14a | 8.01 ± 0.21a |
T1 | 6.23 ± 0.18b | 6.78 ± 0.24c | ||
T2 | 7.15 ± 0.12a | 7.55 ± 0.01a | ||
T3 | 6.85 ± 0.13ab | 6.95 ± 0.42b |